Reguliert
Vorzeitig verkaufbar
- Risikostufe
- Sehr hoch
- Risiko-Rendite
- Mittel
- Start ab
- €500
Airway Shield
Spanien
A Spanish company selling a single-use plastic mouthpiece that helps doctors guide a breathing tube into a patient's windpipe, while shielding the patient's teeth and the medical staff from what the patient breathes out.
Eckdaten
- Geschätzte Rendite
- bis zu 8×
- Schätzung der Plattform
- Unternehmensbewertung
- €8,000,000
- Angebotener Anteil
- 9
- Erwarteter Exit
- 2030
- Start ab
- €1,000
- Zielbetrag
- €800,000
Was Ihnen gehört, wie es sich auszahlen kann, und wann
Was gehört mir?
9 des Unternehmens
Prüfen Sie in den Dokumenten, wie die Anteile gehalten werden und welche Rechte sie gewähren.
Wie kann es sich auszahlen?
Die Plattform schätzt bis zu 8×
In der Regel nur, wenn das Unternehmen verkauft wird oder an die Börse geht. Schätzungen sind eigene Angaben der Plattform.
Wann könnte ich Geld erhalten?
Etwa 2030
Nur wenn es zu einem Verkauf oder Börsengang kommt; vorher sind Anteile schwer verkäuflich.
Kapitalverlustrisiko. Die meisten Startups scheitern; Schätzungen sind eigene Angaben der Plattform. Anteile sind vor einem Exit schwer zu verkaufen.
Würde die KI investieren?
KI 65 MittelUnsere KI gibt diesem Projekt 65 von 100 Punkten: Mittel. So funktioniert der KI-Score
Informationen, keine persönliche Anlageberatung. Der KI-Score bewertet die von der Plattform veröffentlichten Dokumente, kann falsch sein und sagt keine Renditen voraus.
KI-Analyse
KIAirway Shield — Crowdfunding Investor Memo
A Spanish company selling a single-use plastic mouthpiece that helps doctors guide a breathing tube into a patient's windpipe, while shielding the patient's teeth and the medical staff from what the patient breathes out.
Sector: Medical devices (airway management) · Stage: Seed, CE-marked and selling · HQ: Madrid / Santander, Spain · Raise: €800,000 for 9% (maximum €1,000,000) · Platform: Capital Cell
Snapshot
|
1 · Is the price fair? 💶 |
4 / 5 — Broadly supported. The €8M asking price sits below the European seed median implied by Carta's 2025 data, and is a disciplined 2.0x step-up from the company's own 2023 round at €4M — across which it earned a CE mark, ran two patient studies and had a US patent granted. The regulatory sheet also shows discounts: put in €5,000 or more and you pay €49.76 a share instead of €53.79, an effective price of about €7.4M rather than €8M. It looks high only against revenue, a poor measure six months into selling. |
|
2 · Can they reach an exit stage? ⭐ |
AI SCORE 63 / 100 — Average Strongest evidence: an approved, patented product already used on patients, in a category large firms repeatedly buy. Biggest gap: the US Patent Office records the patent covering the device as owned by a different company than the one you would be buying into. |
|
3 · If they do, what could it pay? 🎯 |
Target 8x by 2030 (about 4 years) — the company's own plan. If reached, illustratively 5x–12x gross, or about 4.7x–11.5x after Capital Cell's 8% success fee, and before future dilution. Method: at the €53.79 share price, every €8.8M the company is eventually sold for returns roughly 1x to this round; €45M–€110M is the band into which the two closest recorded airway-device takeovers fall (Inogen/Physio-Assist, up to $45M, 2023; Medtronic/Aircraft Medical, $110M, 2015). |
How to read the score
|
85–100 · Excellent |
All key preconditions for reaching an exit stage are evidenced and strong — rare at this stage |
|
70–84 · Good |
Preconditions largely in place, with specific gaps — named in the questions section |
|
50–69 · Average |
Meaningful preconditions missing or weakly evidenced |
|
30–49 · Weak |
Several core preconditions absent, or the evidence points against them |
|
1–29 · Critical |
Fundamental preconditions are not visible in the evidence |
|
What we could check. We checked 41 of the company's claims against public sources: 22 were confirmed, 5 partly confirmed, 13 could not be found either way, and one was contradicted — the claim that the company owns its patent outright. The FDA designation, the prior fundraises, the public grants, the awards and all four comparable takeovers check out against original filings and press releases. We also have the regulatory sheet the platform must publish (the KIIS), which settles the share price, the type of shares, the fees and the rights you get — and which corrects the campaign on two of them. Revenue, profit margin, cash in the bank and the share register still rest on the company's own materials or were not in the pack we reviewed — see the questions section. |
Three answers, one honest note. The fairness score says whether the price being asked is supported by the benchmarks we could find. The AI Score is our read on whether the building blocks for reaching a sale of the company are in place, judged on the evidence disclosed — it is not a probability of success, and even companies with every building block in place fail more often than they succeed, which is why this kind of investing only works as a small part of a spread-out portfolio. The returns range is an illustration built from named benchmarks, not a forecast. Where something was missing from the pack, it did not lower any score — it appears in the questions list instead, so you can ask the company directly. The listing was reviewed by Capital Cell, a crowdfunding platform licensed by Spain's financial regulator, before it went live. Nothing here is a recommendation.
At a glance
|
✅ Three reasons to look closer |
⚠️ Three reasons for caution |
|
|
|
Deal terms. No terms were identified that would prevent a crowdfund investor from sharing in the upside. The regulatory sheet confirms these are plain ordinary shares that share in whatever a sale produces, with no structure that would hold your return near your money back. Two p… |
Die vollständige Analyse behandelt den Kreditnehmer bzw. das Unternehmen, die Sicherheit, den Cashflow, die Risiken und ein Fazit. Melden Sie sich an, um sie zu lesen.
Informationen, keine persönliche Anlageberatung. Der KI-Score bewertet die von der Plattform veröffentlichten Dokumente, kann falsch sein und sagt keine Renditen voraus.
KI zu diesem Projekt fragen
Melden Sie sich an, um der KI Fragen zu den Dokumenten dieses Projekts zu stellen.
AnmeldenGefällt Ihnen dieses Projekt?
👍 Ja · 0 👎 Nein · 0
Kommentare · 0
- Noch keine Kommentare.
Die Plattform und ähnliche Projekte
Angeboten auf
Ähnliche offene Projekte
Kepplair Evolution
Sowefund
- Geschätzte Rendite
- bis zu 7×
- Schätzung der Plattform
- Unternehmensbewertung
- €60,000,000
Ziel: €9m
Ab €500
Projekt ansehen
Wind Fisher
Sowefund
- Geschätzte Rendite
- bis zu 10×
- Schätzung der Plattform
- Unternehmensbewertung
- €9,961,800
Ziel: €600k
Ab €1,000
Projekt ansehen
Blumana
Sowefund
- Geschätzte Rendite
- bis zu 28×
- Schätzung der Plattform
- Unternehmensbewertung
- €2,799,571
Ziel: €750k
Ab €1,000
Projekt ansehen